These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 33653902)

  • 1. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review.
    Marini A; Bernardini A; Gigli GL; Valente M; Muñiz-Castrillo S; Honnorat J; Vogrig A
    Neurology; 2021 Apr; 96(16):754-766. PubMed ID: 33653902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
    Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years.
    Ruggiero R; Balzano N; Di Napoli R; Fraenza F; Pentella C; Riccardi C; Donniacuo M; Tesorone M; Danesi R; Del Re M; Rossi F; Capuano A
    Front Immunol; 2023; 14():1134436. PubMed ID: 37006303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
    Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
    J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
    Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
    Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
    J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
    Seki M; Kitano S; Suzuki S
    Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
    Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
    J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Skowron F; Egri M; Desestret V; Tilikete C; Psimaras D; Ducray F; Honnorat J
    Neurology; 2021 Feb; 96(6):e866-e875. PubMed ID: 33318162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
    Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system.
    Shi J; Niu J; Shen D; Liu M; Tan Y; Li Y; Huang Y; Cui L; Guan Y; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):481-487. PubMed ID: 31823509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Peripheral Neuropathy and Muscle Disorders as Immune-Related Adverse Events].
    Suzuki S
    Brain Nerve; 2024 May; 76(5):605-611. PubMed ID: 38741503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
    J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.